A carregar...
Evolution of Therapies for Chronic Myelogenous Leukemia
The clinical outcome for patients with chronic myeloid leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKI), compounds which inhibit the activity of the oncogenic BCR-ABL1 protein. Imatinib was the first TKI developed...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3243359/ https://ncbi.nlm.nih.gov/pubmed/22157290 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0b013e31823dec8d |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|